SCHEMBL7607086

SCHEMBL7607086

OCCOCCNc1nc(-c2ccc(Cl)nc2)nc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
LATS1 O95835 1/20 0.56
MAPK1 P28482 2/20 0.54
ALDH1A1 P00352 4/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 2/20 0.54
GBA1 P04062 8/20 0.53
PDE5A O76074 1/20 0.51
KDM4E B2RXH2 3/20 0.50
RECQL P46063 2/20 0.50
MAPT P10636 4/20 0.48
TP53 P04637 3/20 0.48
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C19 P33261 2/20 0.48
POLB P06746 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
HBB P68871 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7633218 0.87 ALDH1A1 (0.56) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL4868364 0.87 MEN1 (0.74) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7609194 0.85 KDM1A (0.55) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL4864697 0.85 MAPK1 (0.73) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7608945 0.85 LATS1 (0.53) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7606647 0.81 LATS1 (0.79) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7606516 0.81 LATS1 (0.58) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL8898682 0.79 APP (0.60) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7612782 0.79 LATS1 (0.56) MEN1KMT2ALATS1MAPK1ALDH1A1
SCHEMBL7277910 0.78 PDE5A (0.69) MEN1KMT2AMAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-02-28 US disclosed
US-5439895-A Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives VHL, MCL1, NFATC1 MEN1 893/4885KMT2A 767/4885LATS1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.